Please login to the form below

Not currently logged in
Email:
Password:

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

Belgium biopharmaceutical company Ablynx has appointed Dr Robert Zeldin to replace Dr Dominique Tersago as its chief medical officer.

A clinical immunologist, Zeldin has more than 15 years combined regulatory and industry experience, having previously served at Merck & Co, Novartis and the FDA.

He has held senior level clinical development positions within pharma and prior to his move into the industry, Zeldin spent several years in private practice and two years as a medical officer at the FDA's Center for Biologics Evaluation and Research.

Ablynx CEO Dr Edwin Moses said: “We are very pleased that someone with Robert's track record and experience is joining Ablynx as chief medical officer.

“Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders.”

3rd December 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics